San Francisco, CA – endpoint Clinical, a leading global interactive response technology (IRT) company, has announced a significant enhancement to its proprietary PULSE platform, reshaping the way IRT is applied to clinical trials.
San Francisco, CA – endpoint Clinical, a leading global interactive response technology (IRT) company, has announced a significant enhancement to its proprietary PULSE platform, reshaping the way IRT is applied to clinical trials.
“Since the initiation of endpoint in 2009, we have been continuously improving IRT through our organic growth model. The result is the industry’s most integrated and powerful combination of patient and clinical supply management,” said Chuck Harris, CEO.
endpoint has recently combined the cutting-edge features of its industry-leading configurable IRT platform, PULSE, with its revolutionary global inventory management tool, DRIVE, into a single, unified and seamless solution. This concept was developed with clinical supply experts across the industry and is packed with innovations. It extends IRT accessibility and affordability to clients’ entire clinical development portfolio, including investigator initiated trials (IIT) and early-phase, late-phase and compassionate use studies.
The IRT industry continues to operate at the protocol-level, despite the true industry need. The PULSE-DRIVE fusion shifts that paradigm to look across protocols, which provides access to novel functionality supporting operations and regulatory needs such as supply pooling, robust temperature-excursion management, and therapeutic- and compound-level reporting. By centralizing cross-protocol data, this solution seamlessly integrates with advanced simulation and optimization solutions to provide accurate upfront and ongoing forecasting for supply planning and operations in the field using actual IRT data.
“One of the key factors to the successful evolution of endpoint’s products is our leadership’s laser-like focus on the IRT space and how it should be transformed,” said Christine Oliver, COO. “We have built our platforms in-house through an unmatched understanding of system integration, hands-on experience in supply chain management, and a relentless focus on the ever-evolving challenges in clinical trial design.”
Read more about endpoint’s solutions at endpointclinical.com.
About endpointendpoint is an interactive response technology (IRT) systems and solutions provider that supports the life sciences industry. Since 2009, we have been working with a single vision in mind - to help sponsors and pharmaceutical companies achieve clinical trial success. Our solutions, realized through the proprietary PULSE platform, have proven to maximize the supply chain, minimize operational costs, and ensure timely and accurate patient dosing. Headquartered in San Francisco, California, endpoint has a global footprint in the APAC region and Europe.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.